Promising pre-clinical data on TG1050 presented at EASL 2013
Pre-clinical data on TG1050 was presented at EASL 2013, which took place in Amsterdam
Promising pre-clinical data on the novel immunotherapeutic TG1050 to treat chronic hepatitis B infection was presented at the European Association for the Study of the Liver Conference (EASL).
That is according to a statement from the biopharmaceutical organisation Transgene, which develops targeted immunotherapy products to treat those with cancer and chronic infectious diseases.
TG1050 is based on a non-replicative Adenovirus 5 vector that encodes three hepatitis B virus (HBV) antigens or related domains.
Chief executive of Transgene, Phillippe Archinard, revealed he was excited that TG1050 was chosen to be presented at this year's EASL in Amsterdam.
He said: "We hope that this presentation will trigger interest in the scientific community as well as discussions with potential partners."
Indeed, Mr Archinard hopes to begin the first-in-human/phase 1 clinical trial next year.
The presentation provided the most up-to-date data that demonstrated the capacity of TG1050 to induce long-lasting HBV-specific memory T cells.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...